The History of the Chemo-Free Model in the Treatment of Acute Promyelocytic Leukemia

Hong-Hu Zhu*

Department of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Acute promyelocytic leukemia (APL) has become a highly curable disease after four decades of endeavors. Thanks to the efforts of investigators throughout the world, the chemo-free concept has become a reality for both low- and high-risk patients. All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) without chemotherapy has become a first-line treatment for newly diagnosed APL and has been adopted in guidelines or expert recommendations from the NCCN and ELN and in China. Though the regimen has achieved great success, challenges still exist. The rate of early death still has not diminished significantly and is a major obstacle to curing all patients. Leukocytosis is the most important factor for ED, and completely abandoning chemotherapy is dangerous for certain patients in practice. To narrow the gap between guidelines and practice, this review aims to examine the history of the chemo-free model for the treatment of APL in the arsenic-alone era (1974–2002) and the arsenic plus ATRA era (2002–present) and provide practical considerations regarding early death.

Keywords: acute promyelocytic leukemia, ATRA, ATO, chemotherapy, early death

THE EVOLUTION OF THE CHEMO-FREE ERA

Arsenic Monotherapy

Although the term “chemo-free” was introduced for APL in 2011, the history of chemo-free practices can be traced back four decades (Figure 1). The chemo-free era can be characterized into two phases: the arsenic monotherapy phase (1974–2002) and the arsenic plus ATRA combination phase (2002–now). Sun et al. from Haerbin, China, reported long-term follow-up results after one injection of ATO-containing monotherapy in 32 patients with newly diagnosed APL between 1974 and 1985 (1). The complete remission (CR) and partial remission rates were 50 and 19%, respectively, and the 5-year overall survival (OS) was 50%. This result was subsequently confirmed by using pure ATO alone in an extension study including 124 patients from the same group (2). Lu et al. first reported the excellent results of a pilot study of 19 patients using oral tetra-arsenic tetra-sulfide (As4S4) alone; the authors reported a CR rate of 100% and a 3-year disease-free survival (DFS) of 76.6% (3). However, the total course of arsenic was >3 years in the above studies.
which affected the quality of life of the patients. Another two studies from India and Iran shortened the postremission course of ATO to 28 weeks (7 months) and reported similar results (CR rate of 86% and 3-year OS of 86%) (4, 5). The 7-month postremission usage of ATO in the above two protocols provided evidence to design the later arsenic plus ATRA-based chemo-free model.

**ATO Plus ATRA**

In 2002, Estey et al. from MD Anderson Cancer Center was the first to investigate the chemo-free model using ATO plus ATRA (CD33-antibody gemtuzumab ozogamicin (GO) for cytoreduction during induction) during induction and postremission treatment (6). Postinduction treatment consisted of four courses of ATO (daily for 5 days/week for 4 weeks every other month; total of 80 doses) and ATRA (2 weeks on/2 weeks off for 7 months). The study included 82 patients, and the CR rate was 92%. The early death rate was 9%, and the estimated 3-year OS was 85%. This result was further confirmed by updated results from the long-term follow-up of the same group, which provided the basis for the subsequent APL0406 study (7, 8). Moreover, Illiand et al. reported an excellent outcome using ATO and ATRA for induction and consolidation, but the inclusion of idarubicin during induction and low-dose cytotoxic agents during maintenance treatment (7) to design this regimen to slightly deviate from the chemo-free goal (9).

Based on the study by Estey et al., Lo-Coco et al. conducted a randomized noninferiority trial, APL0406, using ATRA plus ATO vs. ATRA plus idarubicin for patients with newly diagnosed, non-high-risk (now low-risk) APL (10, 11). The ATRA plus ATO group showed a CR rate of 100% and a 2-year OS of 99% with a median follow-up of 34.4 months. The NCRI AML17 trial aimed to investigate the de-intensification of treatment by randomizing patients irrespective of their risk status between a chemotherapy- and oral RIF-ATRA and IV ATO-ATRA in a randomized controlled trial (14). In the end, we extended this concept to high-risk patients, while only incorporating minimal chemotherapy, between April 2014 and September 2016 (15). All 20 patients achieved CR, and the 3-year OS and EFS rates were 100% and 89.4%, respectively (15).

Oral ATO is another arsenic that was first revived by a group from Hong Kong, who thereafter completed a series of clinical trials on this issue (16–18). Recently, Gill et al., in a 15-year prospective follow-up study in 73 patients with relapsed APL, reported 5-year and 10-year OS of 79.5 and 67.3%, respectively (17). Most recently, the same group using oral ATO, ATRA and chemotherapy, reported that both LFS and OS were 100% at 5 years (18). The above studies also inspired interest in the research and development of oral ATO in the USA and Australia. One oral arsenic, named ORH-2014, has completed a phase I open-label, dose-escalating study which indicate that ORH-2014 at 15 mg is safe, bioavailable, and provides the required arsenic exposure compared to intravenous ATO at the approved dose (0.15 mg/kg) (19). Moreover, the dose of 10mg is recommended in the future phase 2 and phase 3 trials. Oral ATO developed in Australia is also being evaluated by the ALLG phase 1 study (APML5) (ACTRN12616001022459).

**Early Death Is the Major Obstacle to Curing All Patients**

Early death (ED) is commonly defined as death from any cause within 30 days of diagnosis (12) or at any time during induction (10, 11). Details about this definition have been systematically reviewed in recent years (19–33). As a result of selection bias, clinical trial data have underestimated the impact of ED, but a series of epidemiologic studies revealed that a significant proportion of patients continue to suffer early death (27–29). Encouragingly, however, newer epidemiologic studies now suggest that ED rates may be improving (30–33). According to the US SEER database, ED rates...
have improved over time (2000–2004, 25.3%; 2005–2009, 20.6%; 2010–2014, 17.1%) in the ATRA plus chemotherapy era (33).

Whether the ED rate can be further reduced in the ATRA plus ATO era remains uncertain. The most important studies of the most representative groups (PETHEMA, GIMEMA, European APL, MRC, etc.) have reported ED rates of around 5% for more than two decades in the ATRA plus chemotherapy era (34–36). Zhu et al. reported that the ED rate in the ATRA plus ATO group was 5.5% (n = 758) based on the data from three large centers in China, which excluded the patients who died without receiving treatment (37). It seems that no difference of ED rate exists between ATRA plus chemotherapy model and ATRA plus arsenic model. Whether ED rate is different between the two models in the population-based study need to be investigated in the future.

**Toxicity of Arsenic and ATRA**

The common toxicity of ATO plus ATRA or oral RIF plus ATRA had been systematically reviewed by us recently (38). Liver damage, gastrointestinal toxicity, and headache are common (>10%), while prolongation of the QTc interval and rash are rare (<5%), which is unpredictable before treatment and difficult to perform preemptive therapy. The most important and sometime fatal adverse effect before treatment or during induction therapy with arsenic plus ATRA is leukocytosis, defined as a white blood cell (WBC) count over 10 x 109/L. Lou et al. reported that pretreatment WBCs of 10–50 x 109/L and >50 x 109/L had early death rates of 8.7 and 41.2%, respectively (39). Yoon et al. recently reported that progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death and subsequent relapse in patients with APL (40). Patients with a WBC before treatment of 10–43 x 109/L that increased to a WBCmax >43 x 109/L experienced an increased risk of early death (33.3%). The multivariate analysis revealed that a WBCmax >43 x 109/L correlated significantly with both early death and differentiation syndrome. Similarly, Therefore, timely minimization of leukocytosis is urgent, and successful prevention of the occurrence of leukocytosis is better.

**CONCLUSION**

The history of APL treatment is almost miraculous. After four decades of endeavors, APL has evolved from a highly fatal disease into a highly curable disease. A chemo-free treatment using only ATRA and ATO in non-high-risk patients was easily applied in clinical practice and is now recommended by current guidelines (41–46). A complete oral and chemo-free model using oral arsenic and ATRA further simplified the procedures and made home-based treatment a reality for more patients.

Apart from ED, the relapse is another major challenge of APL, especially in high-risk patients (27). Until now, no consensus molecular cytogenetic abnormalities at the time of diagnosis can reliably predict the relapse, but monitoring PML-RARA transcripts after treatment is a confidential tool to predict relapse. Currently, ATO plus ATRA is the first choice for the first relapse of APL after front treatment with ATRA plus chemotherapy or ATRA plus ATO. Autologous HSCT remains an appropriate option for younger patients in molecular remission and allogeneic HSCT reserved for patients with persistent molecular positive or with higher degrees of relapse (43).

From the perspective of history, the story of struggling with APL is nearing its end, and this successful model is expected to be attempted on other malignances.

**AUTHOR CONTRIBUTIONS**

The author confirms being the sole contributor of this work and has approved it for publication.

**ACKNOWLEDGMENTS**

This work was supported by grants from the National Natural Science Foundation of China (81570128 and 81820108004).

**REFERENCES**

1. Sun HD, Ma L, Hu XC, Zhang TD, Rong FX, Wang X, et al. The clinical report of 16 long-term survivors of acute promyelocytic leukemia treated with Ai-Ling 1 and traditional Chinese medicine. Inf Tradit Chin Med (1991) 06:39–41.

2. Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, et al. Seven years’ summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide—an analysis of 242 cases. Zhonghua Xue Ye Xue Za Zhi (2000) 21 (2):67–70.

3. Lu D, Qiu J, Jiang B, Wang Q, Liu KY, Liu YR, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood (2002) 99(9):3136–43. doi: 10.1182/blood.V99.9.3136

4. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukaemia: durable remissions with minimal toxicity. Blood (2006) 107:2627–32. doi: 10.1182/blood-2005-08-3532

5. Ghabavazdeh A, Alimoghadam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol (2006) 17:131–4. doi: 10.1093/annonc/mdi019

6. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood (2006) 107 (9):3469–73. doi: 10.1182/blood-2005-10-4006

7. Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol (2009) 27 (4):304–10. doi: 10.1200/JCO.2008.18.6130

8. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. Blood (2017) 129 (10):1275–83. doi: 10.1182/blood-2016-09-736686

9. Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol (2015) 2(9):e357–66. doi: 10.1016/S2352-3026(15)00115-5
10. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Groupo Italiano Malattie Ematologiche dell’Adulto, the German–Austrian Acute Myeloid Leukemia Study Group, and Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 369(2):111–21. doi: 10.1056/NEJMoa1308874
11. Platzecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German AP1046 Trial. J Clin Oncol (2017) 35(6):605–12. doi: 10.1200/JCO.2016.67.1982
12. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. The UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol (2015) 16(13):1295–305. doi: 10.1016/S1470-2045(15)00193-X
13. Zhu HH, Huang XJ. Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. N Engl J Med (2014) 371(23):2239–41. doi: 10.1056/NEJMoa1412035
14. Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet (2018) 18(1):871–9. doi: 10.1016/S1470-2045(18)30263-X
15. Zhu HH, Liu YR, Jia JS, Qin YZ, Zhao XS, Lai YY. Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. Blood (2018) 131(26):2987–9. doi: 10.1182/blood-2018-02-834051
16. Au WY, Kumana CR, Lee HK, Lin SY, Liu H, Yeung DY, et al. Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood (2011) 118(25):6535–43. doi: 10.1182/blood-2011-05-354530
17. Gill H, Yim R, Lee HHK, Mak V, Lin SY, Kho B, et al. Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study. Cancer (2018) 124(11):2316–26. doi: 10.1002/cncr.31327
18. Gill H, Kumana CR, Yim R, Hwang YW, Chan TSY, Yip SF, et al. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study. Cancer (2019) 125(17):3001–12. doi: 10.1002/cncr.32180
19. Ravandi F, Koumenis I, Johri A, Tallman M, Roboz GJ, Strickland S, et al. Oral arsenic trioxide ORRH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica (2020) 105(6):1567–74. doi: 10.3324/haematol.2019.239583
20. Abedin S, Altman JK. Acute promyelocytic leukemia: preventing early complications and late toxicities. Hematol Am Soc Hematol Educ Program (2016) 2016(1):10–5. doi: 10.1182/asheducation-2016.1.10
21. Norsworthy KJ, Altman JK. Optimal treatment strategies for high-risk acute promyelocytic leukemia. Curr Opin Hematol (2016) 23(2):127–36. doi: 10.1097/MOH.0000000000000215
22. Lehmann S. Early death in acute promyelocytic leukemia. In: O Abla, F Lo coco, MA Sanz, editors. Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database. J Natl Compr Canc Netw (2020) 18(2):169–75. doi: 10.6004/jnccn.2019.7351
23. Zhu HH, HU, Lo Coco F, Jin J. The Simpler, the Better: Oral Arsenic for Acute Promyelocytic Leukemia. Blood (2019) 134(7):597–605. doi: 10.1182/blood.2019000760
24. Lou Y, Ma Y, Sun J, Suo S, Suo T, Hong X, Qian W, et al. Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia. Ann Hematol (2017) 96(11):1793–800. doi: 10.1007/s00277-017-3096-5
25. Yoon JH, Kim HN, Min GJ, Park SS, Jeon YW, Lee SE, et al. Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia. Sci Rep (2019) 9(1):11935. doi: 10.1038/s41598-019-47973-4
26. Zhu HH, Jiang B, Jiang Q, Jiang H, Li J, Huang XJ. Early Death and Outcomes of Patients with APL using arsenic and ATRA as First-Line treatment in real world study. 24-27 September 2017; Rome, Italy. Abstract C0008.
27. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines). In: Acute Myeloid Leukemia. Version 2. 2020-September 3, 2019.
28. Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naez T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukaemiaNet. Blood (2019) 133(15):1630–43. doi: 10.1182/blood-2019-01-894980
44. Ma J. Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi (2014) 35(5):475–77. doi: 10.3760/cma.j.issn.0253-2727.2014.05.024

45. Chinese Society of Hematology, Chinese Medical Doctor Association, Chinese Medical Association and Chinese Medical Doctor Association. Chinese guidelines for diagnosis and treatment of acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi (2018) 39(3):179–83. doi: 10.3760/cma.j.issn.0253-2727.2018.03.002

46. Guidelines of Chinese Society of Clinical Oncology (CSCO). Hematological malignancies. (2019).

Conflict of Interest: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.